We recently published a list of Kevin O’Leary’s Stock Portfolio: 15 Stock Picks for 2025. In this article, we are going to ...

We recently compiled a list of the Retirement Stock Portfolio: 10 Healthcare Stocks to Buy. In this article, we are going to ...

The company reported revenue of $22.5 billion and adjusted earnings of $2.04 per share, compared to the consensus estimates ...

We recently published a list of Jim Cramer is Talking About These 10 Stocks. In this article, we are going to take a look at ...

Johnson & Johnson (JNJ) stock saw a modest uptick, ending the day at $152.89 which represents a slight increase of $6.07 or 4.13% from the prior close of $146.82. The stock opened at $ and touched a ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Many investors also have a go-to methodology that helps guide their buy and ...

Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our Shareholder Yield Investor model based on the published ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...

Johnson & Johnson's Q4 2024 earnings missed EPS expectations, but broadly met revenue targets. Click here to read why JNJ ...

Accel Wealth Management boosted its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 23.5% during the fourth quarter, according to the company in its most recent 13F filing with the ...

Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping analysts’ consensus ...

JNJ boasts a Value Style Score of B and VGM Score of B, and holds a Zacks Rank #3 (Hold) rating. Shares of Johnson & Johnson are trading at a forward earnings multiple of 14.5X, as well as a PEG Ratio ...